Institut Curie;INSERM (Institut National de la Santé et de la Recherche Médicale);CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-
发明人:
申请号：
EP19202570.8
公开号：
EP3616690A1
申请日:
2012.10.03
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1α silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.
